DME Resource Center
Editorially independent content supported with advertising.
Videos

Now Showing

Now Showing

Now Showing

Now Showing

Now Showing

Now Showing

Now Showing

Now Showing

Now Showing

Now Showing

Now Showing

Now Showing

Now Showing
Resources
-
Beyond the Clinical Trials
An educational series on the implications of managing the ocular manifestations of diabetes in real world settings. In Part 1 the series, Raj K. Mutari, MD, of the Midwest Eye Institute in Indianapolis, Indiana, addresses the changing disease trends of diabetes around the world.
-
Beyond the Clinical Trials - Part II
An educational series on the implications of managing the ocular manifestations of diabetes in real world settings. In Part 2 of the series, Gary Scheiner, MS, CDE, a certified diabetes educator, talks about the comanagement of patients and the difficulties all members of a patient’s health care team have in educating about diabetes and motivating patients to be adherent to their care regimen.
-
Beyond the Clinical Trials - Part III
An educational series on the implications of managing the ocular manifestations of diabetes in real world settings. In Part 3 of this ongoing series, Victor H. Gonzalez, MD, of Valley Research Institute in McAllen, Texas, explores the technology necessary to establish a baseline for each patient, how the clinical examination guides the use of imaging, and how to use optical coherence tomography and fluorescein angiography to follow patients over time. An overlooked aspect in the use of imaging, according to Dr. Gonzalez, is the changing reimbursement landscape for retina specialists and how it may change how patients are managed in the very near future.
-
Beyond the Clinical Trials - Part IV
An educational series on the implications of managing the ocular manifestations of diabetes in real world settings. In Part 4 of this ongoing series, two retina specialists present clinical cases that reflect the sometimes challenging aspects of dealing with patients in the clinic on a day-to-day basis. First, Sunir J. Garg, MD, an associate professor of ophthalmology with the Retina Service of Wills Eye Hospital and Thomas Jefferson University, presents a case of a patient who was nonadherent to medical advice—and as a consequence, she may have left vision on the table. Then, Rishi P. Singh, MD, a staff physician at Cole Eye Institute, Cleveland Clinic, medical director of the clinical systems office in Cleveland Clinic, and an assistant professor of ophthalmology at Case Western Reserve University, offers a case of a patient with history of glaucoma but who previously was responsive to intravitreal steroid injections but not to anti-VEGF therapy. Would additional steroid therapy in this patient wind up causing unwanted adverse outcomes?
-
Beyond the Clinical Trials - Part V
An educational series on the implications of managing the ocular manifestations of diabetes in real world settings. In Part 5, Sanket U. Shah, MD, a third-year resident at Indiana University School of Medicine in Indianapolis, Ind., and Raj K. Maturi, MD, of the Midwest Eye Institute in Indianapolis, Ind., share a comparison of the results of two differenttreatments for DME in several patient cases.
-
Beyond the Clinical Trials - Part VI
An educational series on the implications of managing the ocular manifestations of diabetes in real world settings. In Part 6 of the series, Anat Loewenstein, MD, of the Tel Aviv Sourasky Medical Center and Tel Aviv University in Israel, shares several cases in which she treated patients with DME using a corticosteroid implant
-
Beyond the Clinical Trials - Part VII
An educational series on the implications of managing the ocular manifestations of diabetes in real world settings. In Part 7 of the series, Daniel Kiernan, MD, of Ophthalmic Consultants of Long Island in Long Island, N.Y., details his use of anti-VEGF therapy and sustained-release corticosteroids in the treatment of patients with DME. In the patient cases he shares, he also includes a short recap on the cost to maintain each patient’s vision with the chosen treatment.
-
Beyond the Clinical Trials - Part VIII
An educational series on the implications of managing the ocular manifestations of diabetes in real world settings. In Part 8 of the series, Michael A. Singer, MD, of Medical Center Ophthalmology Associates in Texas, shares his treatment strategies in two patients with diabetic eye disease.
-
Beyond the Clinical Trials - Part IX
An educational series on the implications of managing the ocular manifestations of diabetes in real world settings. In Part 9 of the series, John D. Pitcher III, MD, of Eye Associates of New Mexico, gives readers a look at his approaches to treating three patients with diabetic eye disease.
-
Beyond the Clinical Trials - Part X
An educational series on the implications of managing the ocular manifestations of diabetes in real world settings. In Part 10 of the DME Resource Center print series, Andre Witkin, MD, an assistant professor at Tufts Medical Center, shares two cases in which he had to change his strategy for treating patients with DME.
-
Beyond the Clinical Trials - Part XI
An educational series on the implications of managing the ocular manifestations of diabetes in real world settings. In Part 11 of this series, Maria H. Berrocal, MD, an assistant professor in the department of ophthalmology at the University of Puerto Rico, details her management of three patients with DME.
-
Beyond the Clinical Trials - Part XII
An educational series on the implications of managing the ocular manifestations of diabetes in real world settings. In this installment of the DME Resource Center, Part 12, Jeremy D. Wolfe, MD, describes his experience in a small, shortterm clinical trial directly comparing anti-VEGF and corticosteroid therapies in the two eyes of a series of patients with DME. He explores the possible reasons for the differences in outcomes observed in the trial.
Beyond the Clinical Trials - Part XII
An educational series on the implications of managing the ocular manifestations of diabetes in real world settings. In this installment of the DME Resource Center, Part 12, Jeremy D. Wolfe, MD, describes his experience in a small, shortterm clinical trial directly comparing anti-VEGF and corticosteroid therapies in the two eyes of a series of patients with DME. He explores the possible reasons for the differences in outcomes observed in the trial.
Articles
When Your Diabetic Patient Requires Anterior Segment Attenti…
Nathan C. Steinle, MD, and Charles C. Wykoff, MD, PhD
The prevalence of diabetes mellitus continues to increase in the United Stat… Read Article
Novel Treatment Strategies for Diabetic Eye Disease
Pravin U. Dugel, MD
There is no doubt that anti -- VEGF-A monotherapy has revolutionized the tre… Read Article
Tissue-Sparing Laser for Center-Involved DME Not Responsive …
Victor Gonzalez, MD
In patients with center-involved diabetic macular edema (DME), treatment wit… Read Article
Key Takeaways From the Latest Clinical Trials in Diabetic Ey…
Aleksandra Rachitskaya, MD
Several recent trials have examined novel approaches to the treatment of dia… Read Article
Into the Suprachoroidal Space
Ehab N. El Rayes, MD, PhD
Recent insights into retinal physiology suggest that the retinal dysfunction… Read Article
The Latest Data on Anti-Integrin Therapy for Patients With D…
Peter K. Kaiser, MD
In a previous article published in Retina Today earlier this year, I provide… Read Article
Retina News
NEI Award for ‘Retina in a Dish’ A team at the University of Mary… Read Article
Early Intervention in Diabetic Macular Edema
Michael A. Singer, MD
img class="left" src="http://retinatoday.com/images/articles/2017-10/Singer_Mich… Read Article
Case Report: Combined Central Retinal Artery and Vein Occlus…
Ferdinand Rodriguez, MD; Joshua D. Levinson, MD; and Jordana G. Fein, MD, MS
img class="left" src="http://retinatoday.com/images/articles/2017-10/Fein_Jordan… Read Article
Retina News
Positive Phase 3 Results, Regulatory Advances for Spark’s Gene Therapy … Read Article
ILM Peeling During Diabetic Vitrectomy: When and Why
Timothy G. Murray, MD, FACS
The increasing incidence and prevalence of diabetes mellitus in the United S… Read Article
Intravitreal Anti-VEGF Injection Treatment Algorithms for DM…
Christopher M. Aderman, MD, and Sunir J. Garg, MD
Diabetic macular edema (DME) affects an estimated 746,000 Americans.1 Althou… Read Article
Anti-Integrin Therapy in Treatment of DME
Peter K. Kaiser, MD
Integrins have recently emerged as a treatment target in vitreoretinal disea… Read Article
Dry AMD Pipeline: Looking to Intravitreal Therapy
Pravin U. Dugel, MD
The potential of using an oral vehicle for drug delivery in diseases of the … Read Article
Retina News
NONVIRAL GENE THERAPY FOR UVEITIS BEGINS CLINICAL TRIAL A nonviral gene thera… Read Article
Is Automated Interpretation of DR Images in Our Future?
Peter A. Karth, MD, MBA, and Ehsan Rahimy, MD
Recently, the terms artificial intelligence (AI) and machine learning have b… Read Article
Exploring Two Photocoagulation Modes for DME
Caesar K. Luo, MD, and Melissa D. Neuwelt, MD
Continuous wave (CW) laser photocoagulation has been a mainstay in the treat… Read Article
Retina News
LONGER-TERM DME OUTCOMES PREDICTED BY EARLY RESPONSE TO ANTI-VEGF THERAPY Eye… Read Article
Lasers in Current Retina Practice
Mahima Jhingan, MD; Komal Agarwal, MD; and Jay Chhablani, MD
img class="left" src="http://retinatoday.com/images/articles/2017-01/Chhablani_j… Read Article
Tie Fighters
Aron Shapiro; David Hollander, MD; and Lisa Smith
img class="left" src="http://retinatoday.com/images/articles/2017-01/Smith_Lisa_… Read Article
Pharmacologic Treatment of PDR and DME
Stephen G. Schwartz, MD, MBA, and Ingrid U. Scott, MD, MPH
The Diabetic Retinopathy Clinical Research Network (DRCR.net), formed in 200… Read Article
Recapping the Past 12 Months
the staff of Retina Today
We are at the tail end of another successful year for the retina world. It is pr… Read Article
Using EHR Tools to Optimize Ophthalmologic Outcomes in Patie…
Rishi P. Singh, MD, and Ingrid U. Scott, MD, MPH
Although ophthalmologists provide specialized services for patients with dia… Read Article
News
CMS Releases Proposed 2017 ASC Payment Rates for Ophthalmic Services The … Read Article
The Role of Laser in the Pharmacologic Era of Retina
Baruch Kuppermann, MD, PhD
Although the retina subspecialty has largely embraced pharmacology in the tr… Read Article
Vitrectomy With ILM Removal for DME Resistant to Conventiona…
Sergio Rojas, MD, and Ezequiel Diaz Benitez, MD
Diabetic macular edema (DME) is an important cause of visual loss in patient… Read Article
A Postmodern View of Anti-VEGF Treatment
Nancy M. Holekamp, MD
At one time, laser photocoagulation was the only option for treating patient… Read Article
Will a New Low-Cost Option Join the Anti-VEGF Fold?
Brian C. Joondeph, MD, MPS
As physicians, we all know the importance of being reimbursed and paid for s… Read Article
News
Study: Higher Risk for Neurodevelopmental Disabilities With Bevacizumab for ROP … Read Article
Why “Not 20/20” After an Excellent Phacoemulsification S…
Jay Chhablani, MD, and Vivek Gupta, MBBS
Advanced surgical techniques have improved the outcomes of cataract surgery … Read Article
Ocular Drug Delivery Systems
Randall V. Wong, MD
Prior to the adoption of intravitreal injections for the treatment of retina… Read Article
News
RETROSPECTIVE STUDY: L-DOPA WAS PROTECTIVE AGAINST WET AMD Exogenous L-DOPA… Read Article
American Academy of Ophthalmology 2015 Annual Meeting
The American Academy of Ophthalmology (AAO) 2015 Annual Meeting was held Novem… Read Article
Drug Delivery to the Posterior Segment
Daniel D. Esmaili, MD; and David S. Boyer, MD
At a Glance • Intravitreal injection is the current drug delivery meth… Read Article
Treatment of DME With the 0.19-mg Fluocinolone Acetonide Imp…
Scott W. Cousins, MD
As part of this review of sustained-release steroid implants, I will discuss the… Read Article
Dexamethasone Intravitreal Implant: Pharmacology and Clinica…
Yoshihiro Yonekawa, MD; and Jeremy D. Wolfe, MD
The dexamethasone intravitreal implant (Ozurdex, Allergan) is approved by the US… Read Article
Laser Use and the Future of Retina Practice
Anat Loewenstein, MD
At a Glance • Although pharmacologic therapy provides excellent result… Read Article
A New Self-Testing System for Patients With AMD or DME
Raj K. Maturi, MD
At a Glance • Home monitoring of some retinal diseases is desirable be… Read Article
Individualizing Therapy for DME
Antonio Capone Jr, MD
At a Glance • The degree to which VEGF or inflammation is the more imp… Read Article
Examining the Systemic Safety of Anti-VEGF Agents
Karen Roman, Editor-in-Chief
At a Glance • Anti-VEGF agents can enter the circulation and reduce sy… Read Article
A Dual-Mechanism Drug for Vitreoretinal Diseases
Baruch D. Kuppermann, MD, PhD
At a Glance • Integrins are cell surface receptors involved in angioge… Read Article
Incorporating New Technologies Into Practice: The Big Pictur…
Szilárd Kiss, MD
At a Glance • It is important to weigh the visual benefits and potenti… Read Article
Additional Perspectives on Protocol T
Bryan Bechtel, Editor-in-Chief
The results of the DRCR.net Protocol T study have been released to the re… Read Article
What Is New with Anti-VEGF Therapy for DME
Dilsher S. Dhoot, MD, and Dante Pieramici, MD
The landscape for the treatment of diabetic macular edema (DME) is evolving. O… Read Article
The Role of Corticosteroid Implants in DME
Nancy Holekamp, MD
Anti-VEGF drugs are appropriately considered first line therapy for patient… Read Article
What is the Current Role of Laser Therapy in the Management …
Sam E. Mansour, MSc, MD, FRCS(C), FACS
Diabetic macular edema (DME) is a leading cause of vision loss among indivi… Read Article
Crowdsourcing for Rapid Fundus Photograph Interpretation
Christopher J. Brady, MD
Screening for diabetic retinopathy (DR) with retinal fundus examination is … Read Article
Switching Therapy in Patients with DME
David Eichenbaum, MD; John W. Kitchens, MD; and Andrew A. Moshfeghi, MD, MBA
There Are Several Ways to Define Treatment Failure By David Eichenbaum,… Read Article
Ultra-Widefield Imaging: Advancing the Understanding and Man…
Paul E. Tornambe, MD, FACS
The rising incidence of diabetes in the US population and the cresting wave of… Read Article
Retina News
Joint Technical Report Highlights Viability of Telemedicine for ROP Evaluation… Read Article
Exploring the DME Treatment Decision Tree
An Interview with David Eichenbaum, MD
There is now a variety of options for treating patients with diabetic macul… Read Article
Frequently Asked Questions About the Dexamethasone Implant
Jay Chhablani, MD; Paolo Lanzetta, MD; Adrian Koh, MBBS, MMed (Ophth), FRCS (Ed), FAMS; and Michael …
How fast does the DEX implant reduce macular edema, and in which disease states … Read Article
Investigating Treatment Options for Diabetic Macular Edema
Aron Shapiro with Michael Tolentino, MD, and Edward Quinlan, MD
What are some qualifying features that identify patients who will work well in a… Read Article
Status of Sustained-release Steroids for Diabetic Macular Ed…
With David S. Boyer, MD
Retina Today: Where do corticosteroid sustained-release devices fit in the treat… Read Article
Using Aflibercept to Treat Diabetic Macular Edema
Diana V. Do, MD
Untreated diabetic macular edema (DME) can lead to vision loss in patients with … Read Article
Developments in the Treatment of Diabetic Macular Edema
With Quan Dong Nguyen, MD, MSc
Treatments for diabetic macular edema (DME) continue to be developed. Retina Tod… Read Article
A Minimalist Approach to Surgery for Diabetic Retinal Detach…
María H. Berrocal, MD
Vitrectomy has evolved in the past 45 years, from very large incisions with Kasn… Read Article
Multispot and Multiwavelength Lasers for Diabetic Retinopath…
Manish Nagpal, MS, DO, FRCS; Chaitanya Shukla, DNB; and Kartikey Kothari, MS
Since the ETDRS, panretinal photocoagulation (PRP) or macular laser in the form … Read Article
Management of Diabetic Macular Edema in the UK National Heal…
Sahar Al-Husainy, MBChB, FRCS(Ed), MRCOphth; and Jonathan M. Gibson, MB, BS, MD, FRCS(Ed), FRCOphth
In recent years, diabetes mellitus has become a global health problem. In the Un… Read Article
Optimizing Treatment for Diabetic Macular Edema With Laser
Rahul N. Khurana, MD
Although anti-VEGF monotherapy is effective for treating diabetic macular edema … Read Article
Controversies in Vitreoretinal Surgery: Is Vitrectomy an App…
Tarek S. Hassan, MD and Julia A. Haller, MD
These articles are based on the debate-style presentations at the American Acade… Read Article
Multispot Laser Photocoagulation
Sebastien Guigou, MD
Laser photocoagulation is a proven treatment for retinal pathologies and has bee… Read Article
Fluorescein Angiography and Optical Coherence Tomography Cor…
Jay Chhablani, MD; and Aditya Sudhalkar, MD
Fluorescein angiography (FA) and optical coherence tomography (OCT) scans are im… Read Article
advertisement
News

Researchers Test Stem Cell–Based Retinal Implant for Dry AMD With Encouraging Results
Physicians and researchers at the USC Roski Eye Institute have collaborated with other California institutions to show that a first-in-kind stem cell-based retinal i…
GenSight Biologics Announces Topline Results from Phase 3 Clinical Trial of GS010 in Patients with Leber Hereditary Optic Neuropathy (LHON)
GenSight Biologics announced that a phase 3 study of GS010 (rAAV2/2-ND4) in patients with Leber hereditary optic neuropathy (LHON) failed to meet its primary endpoint, with sh…
Treat-Extend-Stop Protocol for Wet AMD: Long-term Outcomes
A retrospective chart review was performed for 71 eyes of 67 patients with neovascular age-related macular degeneration (AMD) treated with intravitreal anti-vascular endotheli…
Patients Regain Sight After Being First to Get Retinal Tissue Engineered From Stem Cells
The first patients to receive a new treatment derived from stem cells for people with wet age-related macular degeneration (AMD) have regained reading vision, according to a r…
Children’s Hospital Los Angeles Treats First Patient on the West Coast Using Gene Therapy
Surgeons of The Vision Center at Children's Hospital Los Angeles completed a revolutionary gene replacement procedure on Tuesday, March 20 at 9:20 am, to restore vision in…